SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages
SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a "Moderate Buy" consensus from five research firms. The stock has a 1-year price target of $9.33. Analysts' ratings include one "sell," three "buy," and one "strong buy." Recent institutional investments have been made, and the stock is currently priced at $3.70. The company focuses on developing human polyclonal immunotherapeutic antibodies.
Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.3333.
Get SAB Biotherapeutics alerts:
- Promising Upsides on these Biotech Penny Stocks
A number of equities research analysts recently commented on SABS shares. Leerink Partnrs raised SAB Biotherapeutics to a "strong-buy" rating in a research note on Wednesday, September 17th. Leerink Partners started coverage on SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an "outperform" rating and a $7.00 target price for the company. Weiss Ratings reiterated a "sell (d)" rating on shares of SAB Biotherapeutics in a research report on Monday. Chardan Capital reissued a "buy" rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, November 17th. Finally, Wall Street Zen raised shares of SAB Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 22nd.
Check Out Our Latest Research Report on SABS
Institutional Trading of SAB Biotherapeutics
Several hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC bought a new position in shares of SAB Biotherapeutics during the 3rd quarter worth approximately $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics during the third quarter worth $32,000. Virtu Financial LLC bought a new position in SAB Biotherapeutics in the third quarter valued at $40,000. HB Wealth Management LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at $618,000. Finally, Woodline Partners LP acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at $5,730,000. Institutional investors and hedge funds own 7.82% of the company's stock.
SAB Biotherapeutics Stock Up 1.6%
Shares of NASDAQ:SABS opened at $3.70 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50. The stock has a market cap of $176.16 million, a price-to-earnings ratio of -1.20 and a beta of 0.58. The company has a 50 day moving average of $3.00 and a 200-day moving average of $2.42. SAB Biotherapeutics has a one year low of $1.00 and a one year high of $6.60.
SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.38. On average, sell-side analysts forecast that SAB Biotherapeutics will post -3.69 earnings per share for the current year.
SAB Biotherapeutics Company Profile
(Get Free Report)SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
Featured Stories
- Five stocks we like better than SAB Biotherapeutics
- Most Volatile Stocks, What Investors Need to Know
- 3 Stocks Poised to Benefit From Google’s AI Breakthough
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
- Consumer Staples Stocks, Explained
- 3 Stocks You’ll Wish You Bought Before 2026
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in SAB Biotherapeutics Right Now?
Before you consider SAB Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SAB Biotherapeutics wasn't on the list.
While SAB Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
